128 related articles for article (PubMed ID: 33249291)
1. Full-coverage TP53 deep sequencing of recurrent head and neck squamous cell carcinoma facilitates prognostic assessment after recurrence.
Kobayashi K; Yoshimoto S; Ando M; Matsumoto F; Murakami N; Omura G; Honma Y; Matsumoto Y; Ikeda A; Sakai A; Eguchi K; Ito A; Ryo E; Yatabe Y; Mori T
Oral Oncol; 2021 Feb; 113():105091. PubMed ID: 33249291
[TBL] [Abstract][Full Text] [Related]
2. All-Exon TP53 Sequencing and Protein Phenotype Analysis Accurately Predict Clinical Outcome after Surgical Treatment of Head and Neck Squamous Cell Carcinoma.
Kobayashi K; Yoshimoto S; Matsumoto F; Ando M; Murakami N; Omura G; Fukasawa M; Matsumoto Y; Matsumura S; Akamatsu M; Hiraoka N; Eigitsu R; Mori T
Ann Surg Oncol; 2019 Jul; 26(7):2294-2303. PubMed ID: 30900104
[TBL] [Abstract][Full Text] [Related]
3. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
4. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.
Ganci F; Sacconi A; Bossel Ben-Moshe N; Manciocco V; Sperduti I; Strigari L; Covello R; Benevolo M; Pescarmona E; Domany E; Muti P; Strano S; Spriano G; Fontemaggi G; Blandino G
Ann Oncol; 2013 Dec; 24(12):3082-8. PubMed ID: 24107801
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutations and survival in squamous-cell carcinoma of the head and neck.
Poeta ML; Manola J; Goldwasser MA; Forastiere A; Benoit N; Califano JA; Ridge JA; Goodwin J; Kenady D; Saunders J; Westra W; Sidransky D; Koch WM
N Engl J Med; 2007 Dec; 357(25):2552-61. PubMed ID: 18094376
[TBL] [Abstract][Full Text] [Related]
6. Expression levels of miR-34-family microRNAs are associated with TP53 mutation status in head and neck squamous cell carcinoma.
Metheetrairut C; Chotigavanich C; Amornpichetkul K; Keskool P; Ongard S; Metheetrairut C
Eur Arch Otorhinolaryngol; 2019 Feb; 276(2):521-533. PubMed ID: 30515607
[TBL] [Abstract][Full Text] [Related]
7. Success of salvage treatment: a critical appraisal of salvage rates for different subsites of HNSCC.
Matoscevic K; Graf N; Pezier TF; Huber GF
Otolaryngol Head Neck Surg; 2014 Sep; 151(3):454-61. PubMed ID: 24894422
[TBL] [Abstract][Full Text] [Related]
8. Analysis of genetic variants of frequently mutated genes in human papillomavirus-negative primary head and neck squamous cell carcinoma, resection margins, local recurrences and corresponding circulating cell-free DNA.
Flach S; Kumbrink J; Walz C; Hess J; Drexler G; Belka C; Canis M; Jung A; Baumeister P
J Oral Pathol Med; 2022 Sep; 51(8):738-746. PubMed ID: 35895622
[TBL] [Abstract][Full Text] [Related]
9. Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation.
Tinhofer I; Stenzinger A; Eder T; Konschak R; Niehr F; Endris V; Distel L; Hautmann MG; Mandic R; Stromberger C; Weichert W; Budach V
Ann Oncol; 2016 Dec; 27(12):2262-2268. PubMed ID: 27681865
[TBL] [Abstract][Full Text] [Related]
10. Associations among smoking, MGMT hypermethylation, TP53-mutations, and relapse in head and neck squamous cell carcinoma.
Matsuda S; Mafune A; Kohda N; Hama T; Urashima M
PLoS One; 2020; 15(4):e0231932. PubMed ID: 32324779
[TBL] [Abstract][Full Text] [Related]
11. Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma.
Ock CY; Son B; Keam B; Lee SY; Moon J; Kwak H; Kim S; Kim TM; Jeon YK; Kwon SK; Hah JH; Lee SH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
J Cancer Res Clin Oncol; 2016 Apr; 142(4):873-83. PubMed ID: 26677030
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
13. Mutated
Kampel L; Feldstein S; Tsuriel S; Hannes V; Carmel Neiderman NN; Horowitz G; Warshavsky A; Leider-Trejo L; Hershkovitz D; Muhanna N
Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759818
[TBL] [Abstract][Full Text] [Related]
14. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
15. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study.
van Houten VM; Leemans CR; Kummer JA; Dijkstra J; Kuik DJ; van den Brekel MW; Snow GB; Brakenhoff RH
Clin Cancer Res; 2004 Jun; 10(11):3614-20. PubMed ID: 15173067
[TBL] [Abstract][Full Text] [Related]
16. [Clinical characteristics and multivariate analysis of prognostic factors in recurrent laryngeal carcinoma].
Chen YF; Chen FJ; Yang AK; Zeng ZY; Song M; Li QL
Ai Zheng; 2004 May; 23(5):584-8. PubMed ID: 15142460
[TBL] [Abstract][Full Text] [Related]
17. The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
Chen TC; Wu CT; Wang CP; Lou PJ; Ko JY; Chang YL
Oral Oncol; 2020 Dec; 111():104945. PubMed ID: 32769036
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck.
Alsner J; Sørensen SB; Overgaard J
Radiother Oncol; 2001 May; 59(2):179-85. PubMed ID: 11325447
[TBL] [Abstract][Full Text] [Related]
19. The prognostic utility of haptoglobin genotypes in squamous cell carcinoma of the head and neck.
Lee CC; Lee MS; Ho HC; Hung SK; Tung YT; Chou P; Su YC
Clin Chem Lab Med; 2009; 47(10):1277-83. PubMed ID: 19743954
[TBL] [Abstract][Full Text] [Related]
20. The genomic architectures of tumour-adjacent tissues, plasma and saliva reveal evolutionary underpinnings of relapse in head and neck squamous cell carcinoma.
Wu P; Xie C; Yang L; Liu Y; Zeng J; Li X; Fang X; Fan Y; Zhao S; Kuang N; Xuan T; Xia X; Yi X; Huang Y; Yu Z; Tang Y
Br J Cancer; 2021 Sep; 125(6):854-864. PubMed ID: 34230611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
